


Oslo, 17 October 2017

In  accordance with the authorisation granted  by the Annual General Meeting 29
May  2017, the Board of Directors of PCI Biotech Holding ASA has awarded a total
of 90,000 share options to key employees.

The  share options are allotted  to the newly hired  Chief Medical Officer, Hans
Olivecrona.  Each share option gives  the right to subscribe  for or acquire one
share  per option (after PCI Biotech Holding ASA's choice), at a strike price of
NOK  22.35, equal to the volume weighted average share price (VWAP) for the last
5 days  of trade prior to the grant date. The options can be exercised with 1/3
of  the options after one  year, further 1/3 after two  years and the last third
after three years. The share options are lapsing in Q3 2022.

After  the  allocation,  Hans  Olivecrona  holds  a  total  portfolio of 90,000
unexercised share options and 0 shares.

The   current  authorisation,  as  of  29 May  2017, allows  for  allocation  of
additional 1,040,000 share options to key employees.

For more information, please contact:
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429

This information is subject to the disclosure requirements pursuant to section
5 -12 of the Norwegian Securities Trading Act.


 
    